Rabourn Amy Zaremba

Rabourn Amy Zaremba appears in our data through filings on Opus Genetics, Inc. shares, published by SEC (Form 4). We count 10 filings; the first trade dates from 10 January 2023 and the latest from 23 April 2026.

The open-market record consists of 2 sales worth €20k, with no purchase. Outside the open market, there are 8 share grants. So far in 2026, the count stands at no purchases and 2 sales.

The latest filing, published on 27 April 2026, reports an open-market sale of €7,309 in Opus Genetics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.